Literature DB >> 27232650

Methylphenidate in Pregnancy: A Multicenter, Prospective, Comparative, Observational Study.

Orna Diav-Citrin1,2,3, Svetlana Shechtman2, Judy Arnon2, Rebecka Wajnberg2, Cornelia Borisch4, Evelin Beck4, Jonathan Luke Richardson5, Pina Bozzo6, Irena Nulman6, Asher Ornoy2,3.   

Abstract

INTRODUCTION: Methylphenidate is a central nervous system stimulant medicinally used in the treatment of attention-deficit disorder with or without hyperactivity (ADD/ADHD). Data on its use in human pregnancy are limited. The primary objective of the study was to evaluate the risk of major congenital anomalies after pregnancy exposure to methylphenidate for medical indications.
METHODS: In a prospective, comparative, multicenter observational study performed in 4 participating Teratology Information Services (in Jerusalem, Berlin, Newcastle upon Tyne, and Toronto) between 1996 and 2013, methylphenidate-exposed pregnancies were compared with pregnancies counseled for nonteratogenic exposure (NTE) after matching by maternal age, gestational age, and year at initial contact.
RESULTS: 382 methylphenidate-exposed pregnancies (89.5% in the first trimester) were followed up. The overall rate of major congenital anomalies was similar between the groups (10/309 = 3.2% [methylphenidate] vs 13/358 = 3.6% [NTE], P = .780). The rates of major congenital anomalies (6/247 = 2.4% [methylphenidate] vs 12/358 = 3.4% [NTE], P = .511) and cardiovascular anomalies (2/247 = 0.8% [methylphenidate] vs 3/358 = 0.8% [NTE], P = .970) were also similar after exclusion of genetic or cytogenetic anomalies and limiting methylphenidate exposure to the period of organogenesis (weeks 4-13 after the last menstrual period). There was a higher rate of miscarriages and elective terminations of pregnancy in the methylphenidate group. Significant predictors for the miscarriages using Cox proportional hazards model were methylphenidate exposure (adjusted hazard ratio [HR] = 1.98; 95% CI, 1.23-3.20; P = .005) and past miscarriage (adjusted HR = 1.35; 95% CI, 1.18-1.55; P < .001).
CONCLUSIONS: The present study suggests that methylphenidate does not seem to increase the risk for major malformations. Further studies are required to establish its pregnancy safety and its possible association with miscarriages. © Copyright 2016 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27232650     DOI: 10.4088/JCP.15m10083

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  5 in total

1.  ADHD Medication Use During Pregnancy and Risk for Selected Birth Defects: National Birth Defects Prevention Study, 1998-2011.

Authors:  Kayla N Anderson; Annelise C Dutton; Cheryl S Broussard; Sherry L Farr; Jennifer N Lind; Susanna N Visser; Elizabeth C Ailes; Stuart K Shapira; Jennita Reefhuis; Sarah C Tinker
Journal:  J Atten Disord       Date:  2018-03-09       Impact factor: 3.256

2.  Association Between Methylphenidate and Amphetamine Use in Pregnancy and Risk of Congenital Malformations: A Cohort Study From the International Pregnancy Safety Study Consortium.

Authors:  Krista F Huybrechts; Gabriella Bröms; Lotte Brix Christensen; Kristjana Einarsdóttir; Anders Engeland; Kari Furu; Mika Gissler; Sonia Hernandez-Diaz; Pär Karlsson; Øystein Karlstad; Helle Kieler; Anna-Maria Lahesmaa-Korpinen; Helen Mogun; Mette Nørgaard; Johan Reutfors; Henrik Toft Sørensen; Helga Zoega; Brian T Bateman
Journal:  JAMA Psychiatry       Date:  2018-02-01       Impact factor: 21.596

Review 3.  Associations of Prescribed ADHD Medication in Pregnancy with Pregnancy-Related and Offspring Outcomes: A Systematic Review.

Authors:  Lin Li; Ayesha C Sujan; Agnieszka Butwicka; Zheng Chang; Samuele Cortese; Patrick Quinn; Alexander Viktorin; A Sara Öberg; Brian M D'Onofrio; Henrik Larsson
Journal:  CNS Drugs       Date:  2020-07       Impact factor: 5.749

Review 4.  Pharmacological Treatment of Attention Deficit Hyperactivity Disorder During Pregnancy and Lactation.

Authors:  Asher Ornoy
Journal:  Pharm Res       Date:  2018-02-06       Impact factor: 4.200

Review 5.  The Effects of Drugs used for the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) on Pregnancy Outcome and Breast-feeding: A Critical Review.

Authors:  Asher Ornoy; Gideon Koren
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.708

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.